23 December 2020According to this recent study, the extent and composition of the pathological response following neoadjuvant dabrafenib and trametinib (DT) in BRAFV600E/K mutant melanoma correlates with recurrence-free survival (RFS), including patients achieving a complete pathological response (pCR). These findings support the need for detailed histological analysis of specimens collected after neoadjuvant therapy.
23 December 2020The purpose of this recent study was to identify risk factors related to the development of a second primary melanoma in a series of patients diagnosed with sporadic melanoma and to establish the estimated incidence rate. Fair‐haired and multiple‐nevi patients might benefit from more intensive prevention measures
23 December 2020According to this recent study, reflectance confocal microscopy (RCM) has a high diagnostic power for malignant melanoma (MM) detection, and unnecessary excisions are reduced compared to dermoscopy.
23 December 2020According to this recent study, melanomas associated with congenital nevi (C-NAMs) are more often central to a congenital nevus, with a clod/globular or structureless brown pattern, typical of young patients. Melanomas associated with acquired nevi (NC-NAMs) are frequently hypopigmented nodules/plaques, eccentric/peripheral, with hypopigmented structureless areas, typical of older patients.
23 December 2020The objective of this recent study was to develop and internally validate a prediction model to calculate the absolute risk of a first keratinocyte carcinoma (KC) in patients with actinic keratosis(AK). It concludes that the risk of KC in patients with AK can be calculated with the use of four easily assessable predictor variables.
15 December 2020The purpose of this recent study was to evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs). It concludes that first-line pembrolizumab monotherapy exhibited promising anti-CSCC activity, with durable responses and manageable safety. PD-L1 positivity appears to be predictive of pembrolizumab efficacy.
15 December 2020This study presents the first interim analysis of the recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) cohort from the 2-cohort—locally advanced and R/M—phase II KEYNOTE-629 study. Pembrolizumab demonstrated effective antitumor activity; clinically meaningful, durable responses; and acceptable safety in primarily elderly patients with R/M cSCC, supporting its use in clinical practice.
14 December 2020The role of ultraviolet rays in producing cancers like melanoma has been considered extensively. According to this recent research, ultraviolet rays prevent imaging information within genes of parent cells on genes of child cells and make some genetic errors in produced DNAs during replications.
14 December 2020Uveal melanoma is the most common eye cancer in adults and is clinically and genetically distinct from skin cutaneous melanoma. Results of this recent study provide new insights into the mechanism of CysLTR2-L129Q oncoprotein signaling and suggest CYSLTR2 as a promising potential therapeutic target in uveal melanoma.
14 December 2020According to this recent study, combined mitogen-activated protein kinase (MAPK)inhibition and anti–PD-L1 therapy may provide treatment options for patients with advanced melanoma.
